Острый лимфобластный лейкоз у детей

1. Shu X.O. Epidemiology of childhood leukemia. Curr Opin Hematol 1997;4(4):227–32.

2. Spector L.G., Ross J.A., Robinson L.L. Epidemiology and Etiology. In: Childhood leukemias, C.-H. Pui (ed.), 2nd ed. Cambridge University Press, 2006.

3. Pui C.-H. Acute lymphoblastic leukemia. In: Childhood leukemias. C.-H. Pui (ed.), 2 nd ed. Cambridge University Press, 2006.

4. Jonsson O.G., Sartain P., Ducore J.M., Buchanan G.R. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes. J Pediatr 1990;117(2 Pt 1):233–7.

5. Gajjar A., Ribeiro R.C., Mahmoud H.H. et al. Overt testicular disease at diagnosis is associated with high risk features and a poor prognosis in patients with childhood acute lymphoblastic leukemia. Cancer 1996;78(11):2437–42.

6. Chicot R.R., Coccia P., Sather H.N. et al. Mediastinal mass in acute lymphoblastic leukemia. Med Pediatr Oncol 1984;12(1):9–16.

7. Riley R.S., Massey D., Jackson-Cook C. et al. Immunophenotypic analysis of acute lymphocytic leukemia. Hematol Oncol Clin North Am 2002;16(2):245–99.

8. Basso G., Buldini B., De Zen L., Orfao A. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001;86(7):675–92.

9. Farhi D.C., Rosenthal N.S. Acute lymphoblastic leukemia. Clin Lab Med 2000;20(1):17–28.

10. Ludwig W.D., Raghavachar A., Thie Immunophenotypic classification of acute lymphoblastic leukaemia. Baillieres Clin Haematol 1994;7(2):235–62.

11. Reddy K.S., Perkins S.L. Advances in the diagnostic approach to childhood lymphoblastic malignant neoplasms. Am J Clin Pathol 2004;122 (Suppl):S3–18.

12. Mrozek K., Heerema N.A, Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004;18(2):115–36.

13. Harrison C.J., Foroni L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002;6(2):91–113.

14. Pui C.H., Crist W.M., Look A.T. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990;76(8):1449–63.

15. Nasedkina T.V., Zharinov V.S., Isaeva E.A. et al. Clinical screening of gene rearrangements in childhood leukemia by using a multiplex polymerase chain reaction-microarray approach. Clin Cancer Res 2003;9(15):5620–9.

16. Raimondi S.C. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993;81(9):2237–51.

17. Johansson B., Mertens F., Mitelman F. Clinical and biological importance of cytogenetic abnormalities in childhood and adult acute lymphoblastic leukemia. Ann Med 2004;36(7):492–503.

18. Carroll W.L., Bhojwani D., Min D.J. et al. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 2006;46(5):570–8.

19. van Delft F.W., Bellotti T., Luo Z. et al. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. Br J Haematol 2005;130(1):26–35.

20. Moos P.J., Raetz E.A., Carlson M.A. et al. Identification of gene expression profiles that segregate patients withchildhood leukemia.Clin Cancer Res 2002;8(10):3118–30.

21. Teuffel O., Betts D.R., Dettling M. et al. Prenatal origin of separate evolution of leukemia in identical twins. Leukemia 2004;18(10):1624–9.

22. Taub J.W., Ge Y. The prenatal origin of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2004;45(1):19–25.

23. Greaves M.F., Maia A.T., Wiemels J.L., Ford A.M. Leukemia in twins: lessons in natural history. Blood 2003;102(7):2321–33. Epub 2003 Jun 5.

24. Yagi T., Hibi S., Tabata Y. et al. Detection of clonotypic IGH and TCR rearrangements in the neonatal blood spots of infants and children with B-cell precursor acute lymphoblastic leukemia. Blood 2000;96(1):264–8.

25. Wiemels J.L., Cazzaniga G., Daniotti M. et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 1999;354(9189):1499–503.

26. Gale K.B., Ford A.M., Repp R. et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 1997;94(25):13950–4.

27. Greaves M.F., Maia A.T., Wiemels J.L., Ford A.M. Leukemia in twins: lessons in natural history. Blood 2003;102(7):2321–33. Epub 2003 Jun 5.

28. Kempski H.M., Sturt N.T. The TELAML1 fusion accompanied by loss of the untranslocated TEL allele in B-precursor acute lymphoblastic leukaemia of childhood. Leuk Lymphoma 2000;40(1–2):39–47.

29. Pui C.H., Sandlund J.T., Pei D. et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004;104(9):2690–6.

30. Rivera G.K., Pinkel D., Simone J.V. et al. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329(18):1289–95.

31. Maurus R., Boilletot A., Otten J. et al. Treatment of acute lymphoblastic leukemia in children with the BFM protocol: a cooperative study and analysis of prognostic factors. Haematol Blood Transfus 1987;30:466–70.

32. Рammond D., Sather H., Nesbit M. et al. Analysis of prognostic factors in acute lymphoblastic leukemia.Med Pediatr Oncol 1986;14(3):124–34.

33. Ludwig W.D., Harbott J., Bartram C.R. et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results Cancer Res 1993;131:269–82.

34. Pui C.H., Behm F.G., Singh B. et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990;75(1):198–202.

35. Shuster J.J., Falletta J.M., Pullen D.J. et al. Prognostic factors in childhood Tcell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990;75(1):166–73.

36. Crist W., Boyett J., Jackson J. et al. Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1989;74(4):1252–9.

37. Miller D.R., Leikin S.L., Albo V.C. et al. Тhree versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 1989;7(3):316–25.

38. Maloney K.W., Shuster J.J., Murphy S. et al. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994. Leukemia 2000;14(12):2276–85.

39. Silverman L.B., Declerck L., Gelber R.D. et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995). Leukemia 2000;14(12):2247–56.

40. Kamps W.A., Veerman A.J., van Wering E.R. et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984–1991. Leukemia 2000;14(12):2240–6.

41. Harms D.O., Janka-Schaub G.E. Cooperative study group for childhood acute lymphoblastic leukemia (COALL): longterm follow-up of trials 82, 85, 89 and 92. Leukemia 2000;14(12):2234–9.

42. Gaynon P.S., Trigg M.E., Heerema N.A. et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995.Leukemia 2000;14(12):2223–33.

43. Schrappe M., Reiter A., Zimmermann M. et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-FrankfurtMunster. Leukemia 2000;14(12):2205–22.

44. Карачунский А.А., Самочатова Е.В., Штакельберг А., Румянцев А.Г. Сравнение протоколов ALL-BFM-90 ALL-MB-91 для лечения острого лимфобластного лейкоза у детей. Педиатрия 1995;(2):10.

45. Schrappe M., Camitta B., Pui C.H. et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000;14(12):2193–4.

46. Dordelmann M., Reiter A., Borkhardt et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999;94(4):1209–17.

47. Asselin B.L., Kreissman S., Coppola D.J. et al. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999;21(1):6–12.

48. Steinherz P.G., Gaynon P.S., Breneman J.C. et al. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996;14(2):389–98.

49. Miller D.R., Coccia P.F., Bleyer W.A. et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. J Clin Oncol 1989;7(12):1807–15.

50. Reiter A., Schrappe M., Ludwig W.D. et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients.Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84(9):3122–33.

51. Hutchinson R.J., Gaynon P.S., Sather H. et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 2003;21(9):1790–7.

52. Nachman J.B., Sather H.N., Sensel M.G. et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338(23):1663–71.

53. Silverman L.B., McLean T.W., Gelber R.D. et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer 1997;80(12):2285–95.

54. Nachman J., Sather H.N., Gaynon P.S. et al. Augmented Berlin-FrankfurtMunster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997;15(6):2222–30.

55. Arico M., Valsecchi M.G., Conter V. et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-FrankfurtMuenster protocol II. Blood 2002;100(2):420–6.

56. Lange B.J., Bostrom B.C., Cherlow J.M. et al. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002;99(3):825–33.

57. Relling M.V., Hancock M.L., Boyett J.M. et al. Prognostic importance of 6mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93(9):2817–23.

58. Relling M.V., Hancock M.L., Rivera G.K. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91(23):2001–8.

59. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet 1996;347(9018):1783–8.

60. Gale R.P., Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet 1991;338(8778):1315–8.

61. Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1991;8(4):301–12. Erratum: Pediatr Hematol Oncol 1992;9(2):following 198.

62. Koren G., Ferrazini G., Sulh H. et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 1990;323(1):17–21.

63. Pinkel D., Woo S. Prevention and treatment of meningeal leukemia in children. Blood 1994;84(2):355–66.

64. Aur R.J., Simone J., Hustu H.O. et al. Central nervous system therapy and combination chemotherapy of Childhood lymphocytic leukemia. Blood 1971;37(3):272–81.

65. Sullivan M.P., Chen T., Dyment P.G. et al. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study. Blood 1982;60(4):948–58.

66. Jones B., Freeman A.I., Shuster J.J. et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 1991;19(4):269–75.

67. Tubergen D.G., Gilchrist G.S., O'Brien R.T. et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol 1993;11(3):520–6.

68. Gajjar A., Harrison P.L., Sandlund J.T. et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood 2000;96(10):3381–4.

69. Dutch Childhood Oncology Group; te Loo D.M., Kamps W.A., van der Doesvan den Berg A. et al. Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group. J Clin Oncol 2006;24(15):2332–6.

70. Pui C.H., Mahmoud H.H., Rivera G.K. et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998;92(2):411–5.

71. Kamps W.A., Bokkerink J.P., Hakvoort-Cammel F.G. et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991–1996). Leukemia 2002;16(6):1099–111.

72. Relling M.V., Rubnitz J.E., Rivera G.K. et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999;354(9172):34–9.

73. Szczepanski T., Orfao A., van der Velden V.H. et al. Minimal residual disease in leukaemia patients. Lancet Oncol 2001;2(7):409–17.

74. van der Velden V.H., Hochhaus A., Cazzaniga G. et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17(6):1013–34.

75. Szczepanski T., Flohr T., van der Velden V.H. et al. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002;15(1):37–57.

76. San Miguel J.F., Ciudad J., Vidriales M.B. et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol 1999;32(3):175–85.

77. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121(6):823–38.

78. Campana D., Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002;15(1):1–19.

79. van Dongen J.J., Macintyre E.A., Gabert J.A. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13(12):1901–28.

80. Coustan-Smith E., Sancho J., Behm et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100(1):52–8.

81. Coustan-Smith E., Sancho J., Hancock M.L. et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96(8):2691–6.

82. Biondi A., Valsecchi M.G., Seriu T.et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000;14(11):1939–43.

83. van Dongen J.J., Seriu T., PanzerGrumayer E.R. et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352(9142):1731–8.

84. Uckun F.M., Nachman J.B., Sather H.N. et al. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma 1999;33(1–2):101–6.

85. Uckun F.M., Nachman J.B., Sather H.N. et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer 1998;83(9):2030–9.

86. Cazzaniga G., Lanciotti M., Rossi V. et al. Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. Br J Haematol 2002;119(2):445–53.

87. Arico M., Valsecchi M.G., Camitta B. et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342(14):998–1006.

88. Schrappe M., Arico M., Harbott J. et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998;92(8):2730–41.

89. Jones L.K., Saha V. Philadelphia positive acute lymphoblastic leukaemia of childhood. Br J Haematol 2005;130(4):489–500.

90. Druker B.J., Sawyers C.L., Kantarjian H. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038–42. Erratum: N Engl J Med 2001;345(3):232.

91. Thomas D.A., Faderl S., Cortes J. et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103(12):4396–407.

92. Biondi A., Cimino G., Pieters R., Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000;96(1):24–33.

93. Chessells J.M., Harrison C.J., Watson S.L. et al. Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987–1999. Br J Haematol 2002;117(2):306–14.

94. Ferster A., Benoit Y., Francotte N. et al. Treatment outcome in infant acute lymphoblastic leukemia. Children Leukemia Cooperative Group--EORTC. European Organization for Research and Treatment of Cancer. Blood 2000;95(8):2729–31.

95. Ramakers-van Woerden N.L., Beverloo H.B., Veerman A.J. et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia 2004;18(3):521–9.

96. Kosaka Y., Koh K., Kinukawa N. et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood 2004;104(12):3527–34.

97. Nagayama J., Tomizawa D., Koh K. et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. Blood 2006;107(12):4663–5. Epub 2006 Feb 14.

98. Jacobsohn D.A., Hewlett B., Morgan E. et al. Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11(12):999–1005.

99. Pui C.H., Gaynon P.S., Boyett J.M. et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002;359(9321):1909–15.

100. Sanders J.E., Im H.J., Hoffmeister P.A. et al. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood 2005;105(9):3749–56.

101. Supportive care of children with cancer: Current therapy and guidelines from the Children's Oncology Group The Johns Hopkins University Press. A.J. Altman (ed.). 3rd ed. 2004.

102. Macfarlane R.J., McCully B.J., Fernandez C.V. Rasburicase prevents tumor lysis syndrome despite extreme hyperleukocytosis. Pediatr Nephrol 2004;19(8):924–7.

103. Bosly A., Sonet A., Pinkerton C.R. et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98(5):1048–54.

104. Hughes W.T., Armstrong D., Bodey G.P. et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997;25(3):551–73.

105. Leung W., Hudson M., Zhu Y. et al. Late effects in survivors of infant leukemia. Leukemia 2000;14(7):1185–90.

106. Walter A.W., Hancock M.L., Pui C.H. et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol 1998;16(12):3761–7.

107. Bhatia S. Late effects among survivors of leukemia during childhood and adolescence.Blood Cells Mol Dis 2003;31(1):84–92.

108. Shusterman S., Meadows A.T. Long term survivors of childhood leukemia. Curr Opin Hematol 2000;7(4):217–22.